Are you stuck wondering what to do with Bayer shares after their rollercoaster ride? You are not alone. After a tough few years, Bayer’s stock story is taking some intriguing turns that could mean the tides are shifting. This year alone, the company’s share price has surged nearly 42% from its lows at the start of the year. This is a powerful rebound that stands out in a challenging global market. However, in the past week, the price slipped 2.7%, sparking fresh debate about whether this is a pause or a sign of deeper issues.

If you zoom out, Bayer’s five-year return is still deep in the red at -42.5%, painting the picture of a company that has struggled to regain investor confidence following years of uncertainty and headline-grabbing lawsuits. Still, that recent momentum hints the market might be recalibrating its risk assessment, possibly driven by gradual legal resolutions and signs of renewed business focus. While it is true last year delivered only a modest 3.5% gain, there is a subtle shift in mood that could signal further growth potential, especially for patient investors willing to ride out the volatility.

So how do you tell if Bayer is really undervalued, or just a value trap? Our valuation analysis gives Bayer a score of 5 out of 6, meaning it looks undervalued on almost every standard check we use. In the next section, we will break down each of those valuation approaches and set you up to make a smarter call on Bayer’s stock. Stick around, because the best way to understand this company’s true value might surprise you.

Bayer delivered 3.5% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry.

A Discounted Cash Flow (DCF) model estimates a company’s value by projecting its future free cash flows and discounting them back to today’s value. This gives investors an idea of what the company is really worth, based on expected cash generation rather than market hype.

For Bayer, the DCF model used is a 2 Stage Free Cash Flow to Equity approach. The most recent annual Free Cash Flow reported was approximately €4.4 billion. Analyst estimates provide projections for the next few years, forecasting gradual growth with free cash flows expected to rise to over €5.0 billion by 2029. Beyond the analyst coverage, Simply Wall St extrapolates the trend further, projecting that by 2035, Bayer’s free cash flows could reach nearly €6.4 billion, all discounted appropriately to reflect present-day value.

Based on these projections, the estimated intrinsic value of Bayer shares is €144.56. This is 81.0% above the current trading price, indicating that the stock appears deeply undervalued by this measure.

Result: UNDERVALUED

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Bayer.

Our Discounted Cash Flow (DCF) analysis suggests Bayer is undervalued by 81.0%. Track this in your watchlist or portfolio, or discover more undervalued stocks.

Another popular way investors value companies is by using the Price-to-Sales (P/S) ratio. The P/S ratio is especially useful for companies like Bayer, where profits might have recently been weighed down by one-off events or exceptional charges, but the company’s underlying sales remain strong and steady. This multiple is well suited for established businesses in sectors such as pharmaceuticals, where consistent revenue generation is key, even if earnings occasionally fluctuate.

Typically, the “right” P/S ratio for a company depends on how fast it is expected to grow, its risk profile, and how profitably it turns sales into profits. Higher growth and wider profit margins tend to justify higher P/S ratios, while increased risks or weaker margins tend to pull them lower.

Currently, Bayer’s P/S ratio stands at 0.59x. This is significantly below both the industry average (2.84x) and the average for its closest peers (1.89x), raising the question of whether the stock is undervalued or the market is pricing in extra risks. To answer that, Simply Wall St’s “Fair Ratio” takes a more nuanced approach. By factoring in Bayer’s earnings growth outlook, profit margin, market cap, and sector risks, the Fair Ratio comes in at 1.52x. This proprietary metric is considered more reliable than a simple peer or industry comparison because it tailors the benchmark to the company’s own prospects and challenges.

With Bayer’s actual P/S ratio well below its Fair Ratio, there appears to be considerable upside if the company delivers even modest improvement from here.

Result: UNDERVALUED

PS ratios tell one story, but what if the real opportunity lies elsewhere? Discover companies where insiders are betting big on explosive growth.

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives. A Narrative is simply your story or viewpoint about a company, connecting what you believe about its future to your own forecasts and a fair value, bringing the numbers to life.

On the Simply Wall St platform, Narratives are an easy, flexible tool found on each company’s Community page. They help users like you link Bayer’s business story to forecasts for future sales, earnings, and margins, and show what price that story implies the stock should be worth.

Narratives let you compare your fair value for Bayer to its current price, so you can make clearer buy or sell decisions based on scenarios you actually believe in rather than just the consensus. These Narratives update automatically as news or earnings arrive, so your perspective stays current and relevant without any heavy lifting.

For example, one investor might see Bayer thriving on innovation, forecasting €4.2 billion in earnings by 2028 and a €39 share price target. Another investor, more cautious about legal and regulatory setbacks, might expect only €2.0 billion in earnings and a €23 target. Narratives put these differing views side by side so you can benchmark, stress test, and act with confidence.

Do you think there's more to the story for Bayer? Create your own Narrative to let the Community know!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include BAYN.xtra.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com